Doxapram to improve diaphragm movement during spontaneous breathing trials in ventilated COPD patients
The Influence of Doxapram Administration on Diaphragmatic Excursion in Mechanically Ventilated Patients With Chronic Obstructive Pulmonary Disease Undergoing Spontaneous Breathing Trial: a Prospective Observational Study
This trial will test whether giving IV doxapram helps the diaphragm move more in people with moderate to severe COPD who are on a ventilator and doing a spontaneous breathing trial.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 35 (estimated) |
| Ages | 20 Years to 65 Years |
| Sex | All |
| Sponsor | Cairo University Academic / other |
| Locations | 1 site (Cairo, Cairo Governorate) |
| Trial ID | NCT07022704 on ClinicalTrials.gov |
What this trial studies
This is a single-center observational protocol in which intravenous doxapram is administered during spontaneous breathing trials in mechanically ventilated patients with moderate to severe COPD. Diaphragmatic excursion will be measured by an expert using respiratory muscle ultrasound before and after doxapram administration. Patients with doxapram allergy, neuromuscular disorders, or inability to visualize the diaphragm will be excluded. The study is conducted at Cairo University and collects physiologic ultrasound endpoints rather than clinical outcomes like weaning success.
Who should consider this trial
Good fit: Adults with moderate to severe COPD who are mechanically ventilated and undergoing a spontaneous breathing trial without allergy to doxapram and with an evaluable diaphragm on ultrasound.
Not a fit: Patients with neuromuscular disorders, a known allergy to doxapram, or when the diaphragm cannot be imaged are unlikely to benefit from this protocol.
Why it matters
Potential benefit: If successful, the findings could support using doxapram to enhance diaphragm movement and potentially help clinicians during weaning from mechanical ventilation.
How similar studies have performed: Respiratory stimulants like doxapram have historical use and mixed evidence for improving ventilation, but using doxapram specifically to increase diaphragmatic excursion during spontaneous breathing trials is relatively novel and not well established.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients with moderate to severe chronic obstructive pulmonary disease undergoing spontaneous breathing trial Exclusion Criteria: * Refusal Allergy to doxapram neuromuscular disorders inability to evaluate the diaphragm
Where this trial is running
Cairo, Cairo Governorate
- Cairo University — Cairo, Cairo Governorate, Egypt (Recruiting)
Study contacts
- Study coordinator: Mina Helmy, MD
- Email: dr_mina20002010@yahoo.com
- Phone: +201007174836
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.